Vornov, J. J., Peters, D., Nedelcovych, M., Hollinger, K., Rais, R., & Slusher, B. S. (2020). Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain. Neurochem Res, 45(6), 1256-1267.
Lemberg, K. M., Vornov, J. J., Rais, R., & Slusher, B. S. (2018). We’re Not “DON†Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine. Mol Cancer Ther, 17(9), 1824-1832.
Wozniak, K. M., Vornov, J. J., Wu, Y., Liu, Y., Carozzi, V. A., Rodriguez-Menendez, V. et al. (2018). Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery. Cancer Res, 78(3), 817-829.
Chiorazzi, A., Wozniak, K. M., Rais, R., Wu, Y., Gadiano, A. J., Farah, M. H. et al. (2018). Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models. Eur J Pharmacol, 840, 89-103.
Wozniak, K. M., Vornov, J. J., Wu, Y., Nomoto, K., Littlefield, B. A., DesJardins, C. et al. (2016). Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity. Cancer Res, 76(11), 3332-3339.
Vornov, J. J., Hollinger, K. R., Jackson, P. F., Wozniak, K. M., Farah, M. H., Majer, P. et al. (2016). Still NAAG’ing After All These Years: The Continuing Pursuit of GCPII Inhibitors. Adv Pharmacol, 76, 215-255.
Rais, R., Jiang, W., Zhai, H., Wozniak, K. M., Stathis, M., Hollinger, K. R. et al. (2016). FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities. JCI Insight, 1(12).
Garner, R., Gopalakrishnan, S., McCauley, J. A., Bednar, R. A., Gaul, S. L., Mosser, S. D. et al. (2015). Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist. Pharmacol Res Perspect, 3(6), e00198.
Wozniak, K. M., Vornov, J. J., Mistry, B. M., Wu, Y., Rais, R., & Slusher, B. S. (2015). Gastrointestinal delivery of propofol from fospropofol: its bioavailability and activity in rodents and human volunteers. J Transl Med, 13, 170.
Vornov, J. J., Wozniak, K. M., Wu, Y., Rojas, C., Rais, R., & Slusher, B. S. (2013). Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism. J Pharmacol Exp Ther, 346(3), 406-413.
Wozniak, K. M., Wu, Y., Vornov, J. J., Lapidus, R., Rais, R., Rojas, C. et al. (2012). The orally active glutamate carboxypeptidase II inhibitor E2072 exhibits sustained nerve exposure and attenuates peripheral neuropathy. J Pharmacol Exp Ther, 343(3), 746-754.